Synpromics and UniQure, new Collaboration in Gene Therapy.

05/03/2015 - 2 minutes

Synpromics has formed a collaboration with uniQure, the Dutch pioneer in human gene therapy, to develop synthetic promoters with specific application in the delivery of gene therapies to liver.

Synpromics, a leading synthetic biology company, will use its unique approach to develop synthetic promoters with upregulated, liver cell specific, activity whilst also decreasing the promoter molecular size to optimize the packaging efficiency of Adeno-Associated Virus (AAV).

AAV is a small virus which infects human cells but does not cause disease, which turns it into a perfect vector for gene therapy uses. AAV-based vectors have been found to affect long-term therapeutic protein expression in humans, which can result in long-lasting treatment for patients.
The work is also supported by Scottish Enterprise through a grant awarded from its SMART: SCOTLAND scheme, which provides financial support to Small to Medium Enterprises across Scotland.

Dr David Venables, CEO of Synpromics, commented, “Synpromics are very pleased to undertake this collaboration with uniQure, and have a further opportunity to demonstrate the utility of our synthetic promoter technology to gene therapy applications.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

You might also be interested in the following:

Support Us

Become a Member